A recent study found that continued therapy with a combination regimen until disease progression improves outcomes in patients with newly diagnosed multiple myeloma who are not eligible for ASCT.READ MORE
The potential impact of CAR-T therapies should not be underestimated, nor should their complexity, which is why a broader understanding of stakeholder knowledge and perception may be critical to their adoption and use. READ MORE
October 18-20 marked the annual Association of Community Cancer Centers (ACCC) National Oncology Conference. Key opinion leaders convened in Nashville, Tennessee to share cutting-edge ideas, strategies, and practical takeaways for transforming patient care in cancer programs. READ MORE
A recent analysis showed which therapy option as the most cost-effective in pretreated multiple myeloma?